Literature DB >> 14519328

Lactating females Syrian hamster (Mesocricetus auratus) show protection against experimental Leishmania infantum infection.

P Gomez-Ochoa1, F M Gascon, J Lucientes, V Larraga, J A Castillo.   

Abstract

The Syrian hamster (Mesocricetus auratus) is the best animal model for human leishmaniosis, an emergent disease that causes 400,000 new cases every year. The main objective of this assay was to prove the relationship between female lactation, which implies hyperprolactinaemia (IFN-gamma, IL-12, IL-2 and TNF-alpha elevated), and leishmaniosis (IFN-gamma, IL-12, IL-2 and TNF-alpha diminished). The results demonstrate the clear implication of lactation in immune response. The infected lactating females did not show any symptoms of sickness, a 24 g mean increase was noticed, throughout the assay they were negative in the indirect diagnosis test (Direct Agglutination Test (DAT)), and in the direct diagnosis tests (N-N-N isolation, tissue impressions).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519328     DOI: 10.1016/s0304-4017(03)00209-7

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  3 in total

1.  Effect of hyperprolactinaemia on Toxoplasma gondii prevalence in humans.

Authors:  Katarzyna Dzitko; Sebastian Malicki; Jan Komorowski
Journal:  Parasitol Res       Date:  2007-12-20       Impact factor: 2.289

2.  Prolactin as immune cell regulator in Toxocara canis somatic larvae chronic infection.

Authors:  Víctor Hugo Del Río-Araiza; Karen Elizabeth Nava-Castro; Fernando Alba-Hurtado; Andrés Quintanar-Stephano; Hugo Aguilar-Díaz; Marco Antonio Muñoz-Guzmán; Pedro Ostoa-Saloma; María Dolores Ponce-Regalado; Jorge Morales-Montor
Journal:  Biosci Rep       Date:  2018-07-31       Impact factor: 3.840

3.  The relation of serum prolactin levels and Toxoplasma infection in humans.

Authors:  A Mohammadpour; H Keshavarz; M Mohebali; M Salimi; A Teimouri; S Shojaee
Journal:  Int J Gen Med       Date:  2018-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.